Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.

Shi Y, Lei K, Jia Y, Ni B, He Z, Bi M, Wang X, Shi J, Zhou M, Sun Q, Wang G, Chen D, Shu Y, Liu L, Guo Z, Liu Y, Yang J, Wang K, Xiao K, Wu L, Yi T, Sun D, Kang M, Ma T, Mao Y, Shi J, Tang T, Wang Y, Xing P, Lv D, Liao W, Luo Z, Wang B, Wu X, Zhu X, Han S, Guo Q, Liu R, Lu Z, Zhang J, Fang J, Hu C, Ji Y, Liu G, Lu H, Wu D, Zhang J, Zhu S, Liu Z, Qiu W, Ye F, Yu Y, Zhao Y, Zheng Q, Chen J, Pan Z, Zhang Y, Lian W, Jiang B, Qiu B, Zhang G, Zhang H, Chen Y, Chen Y, Duan H, Li M, Liu S, Ma L, Pan H, Yuan X, Yuan X, Zheng Y, Gao E, Zhao L, Wang S, Wu C.

Open source

DOI: 10.1002/cac2.12179
Published: 2021-06-29
Container: Cancer Commun (Lond)
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cac2.12179,
  title = {Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.},
  author = {Shi Y and  Lei K and  Jia Y and  Ni B and  He Z and  Bi M and  Wang X and  Shi J and  Zhou M and  Sun Q and  Wang G and  Chen D and  Shu Y and  Liu L and  Guo Z and  Liu Y and  Yang J and  Wang K and  Xiao K and  Wu L and  Yi T and  Sun D and  Kang M and  Ma T and  Mao Y and  Shi J and  Tang T and  Wang Y and  Xing P and  Lv D and  Liao W and  Luo Z and  Wang B and  Wu X and  Zhu X and  Han S and  Guo Q and  Liu R and  Lu Z and  Zhang J and  Fang J and  Hu C and  Ji Y and  Liu G and  Lu H and  Wu D and  Zhang J and  Zhu S and  Liu Z and  Qiu W and  Ye F and  Yu Y and  Zhao Y and  Zheng Q and  Chen J and  Pan Z and  Zhang Y and  Lian W and  Jiang B and  Qiu B and  Zhang G and  Zhang H and  Chen Y and  Chen Y and  Duan H and  Li M and  Liu S and  Ma L and  Pan H and  Yuan X and  Yuan X and  Zheng Y and  Gao E and  Zhao L and  Wang S and  Wu C.},
  year = {2021},
  journal = {Cancer Commun (Lond)},
  doi = {10.1002/cac2.12179},
  url = {https://doi.org/10.1002/cac2.12179}
}

RIS

TY  - JOUR
TI  - Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
AU  - Shi Y
AU  -  Lei K
AU  -  Jia Y
AU  -  Ni B
AU  -  He Z
AU  -  Bi M
AU  -  Wang X
AU  -  Shi J
AU  -  Zhou M
AU  -  Sun Q
AU  -  Wang G
AU  -  Chen D
AU  -  Shu Y
AU  -  Liu L
AU  -  Guo Z
AU  -  Liu Y
AU  -  Yang J
AU  -  Wang K
AU  -  Xiao K
AU  -  Wu L
AU  -  Yi T
AU  -  Sun D
AU  -  Kang M
AU  -  Ma T
AU  -  Mao Y
AU  -  Shi J
AU  -  Tang T
AU  -  Wang Y
AU  -  Xing P
AU  -  Lv D
AU  -  Liao W
AU  -  Luo Z
AU  -  Wang B
AU  -  Wu X
AU  -  Zhu X
AU  -  Han S
AU  -  Guo Q
AU  -  Liu R
AU  -  Lu Z
AU  -  Zhang J
AU  -  Fang J
AU  -  Hu C
AU  -  Ji Y
AU  -  Liu G
AU  -  Lu H
AU  -  Wu D
AU  -  Zhang J
AU  -  Zhu S
AU  -  Liu Z
AU  -  Qiu W
AU  -  Ye F
AU  -  Yu Y
AU  -  Zhao Y
AU  -  Zheng Q
AU  -  Chen J
AU  -  Pan Z
AU  -  Zhang Y
AU  -  Lian W
AU  -  Jiang B
AU  -  Qiu B
AU  -  Zhang G
AU  -  Zhang H
AU  -  Chen Y
AU  -  Chen Y
AU  -  Duan H
AU  -  Li M
AU  -  Liu S
AU  -  Ma L
AU  -  Pan H
AU  -  Yuan X
AU  -  Yuan X
AU  -  Zheng Y
AU  -  Gao E
AU  -  Zhao L
AU  -  Wang S
AU  -  Wu C.
PY  - 2021
JO  - Cancer Commun (Lond)
DO  - 10.1002/cac2.12179
UR  - https://doi.org/10.1002/cac2.12179
ER  -

APA

Y, S., K, L., Y, J., B, N., Z, H., M, B., X, W., J, S., M, Z., Q, S., G, W., D, C., Y, S., L, L., Z, G., Y, L., J, Y., K, W., K, X., L, W., T, Y., D, S., M, K., T, M., Y, M., J, S., T, T., Y, W., P, X., D, L., W, L., Z, L., B, W., X, W., X, Z., S, H., Q, G., R, L., Z, L., J, Z., J, F., C, H., Y, J., G, L., H, L., D, W., J, Z., S, Z., Z, L., W, Q., F, Y., Y, Y., Y, Z., Q, Z., J, C., Z, P., Y, Z., W, L., B, J., B, Q., G, Z., H, Z., Y, C., Y, C., H, D., M, L., S, L., L, M., H, P., X, Y., X, Y., Y, Z., E, G., L, Z., S, W., & C., W. (2021). Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.. Cancer Commun (Lond). https://doi.org/10.1002/cac2.12179

Source records

europe-pmc · retrieved 2026-09-26T22:29:28.236Z
doaj · retrieved 2026-09-26T22:29:28.248Z